Therefore, given the reciprocal alliances, conditions and agreements set out in them, and for other good and valuable counterparties whose entry and sufficiency are recognized, Pfizer and Trevena agree as follows: 7. This 2nd Amendment can be executed in two or more considerations, each considered original and all forming the same agreement together. Pfizer and Trevena want to amend the agreement to reflect their mutual agreement, as provided for by this second amendment. Pfizer agrees to fully support the technical transfer plan and implement the plan as soon as possible. Trevena Inc :: TREVENA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK. Dez 9 (Reuters) – Pfizer Inc :: TREVENA – CO, PFIZER ENTERED INTO AMENDMENT TO DEVELOPMENT & SUPPLY AGREEMENT, DATED DEC. 15, 2016.TREVENA INC – AMENDMENT MODIFIES PFIZER DEAL TERMINATION RIGHTS. On December 4, 2019, Trevena, Inc. (the „company“) and Pfizer CenterOne Group of Pfizer Inc. („Pfizer“) made an amendment (December 2, 2019) (the „change“) to the development and supply contract of December 15, 2016 (the „agreement“). In accordance with the amendment, the company and Pfizer agreed: (i) to specify, among other things, that the first „year of negotiation“ begins after the month in which the company concludes its first commercial sale in good faith of a product manufactured by Pfizer pursuant to the agreement and (ii) to amend termination rights so that each party can terminate the contract if the U.S. Food and Drug Administration or any other regulatory authority does not grant administrative authorization for the product covered by the agreement by December 31, 2021.
. 12.08. (Reuters) – Trevena Inc :: TREVENA ANNOUNCES PRICING OF 50 MILLION PUBLIC OFFERING OF COMMON STOCK. TREVENA INC – PRICED UNDERWRITTEN PUBLIC OFFERING OF 21.7 MILLION SHARES AT 2.30 PER SHARE. 20.08. (Reuters) – Trevena Inc ::TREVENA ANNOUNCES RECEIPT OF MILESTONE PAYMENT UNDER PARTNERSHIP IN CHINA WITH JIANGSU NHWA PHARMACEUTICAL CO. TREVENA INC – RECEIVED A 3 MILLION MILESTONE PAYMENT FROM ITS PARTNER IN CHINA FOR U.S. APPROVAL OF OLINVYK. TREVENA INC – EXPECTS TO RECEIVE FUTURE MILESTONE PAYMENTS, AS WELL AS A 10% ROYALTY ON NET SALES OF OLINVYK IN CHINA. . Post 1.01 Registration in a final agreement.
. . . March 12 (Reuters) – Trevena Inc :: TREVENA REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTATS. Q4 LOSS PER SHARE 0.07.UPDATED GUIDANCE ON EXTENDED CASH RUNWAY, FUNDING OPERATIONS INTO Q1 2021.PDUFA DATES AUGUST 7, 2020 FOR IV OLICERIDINE; THE FDA IS THE COMPLETE RESUBMISSION NDA. INITIATIVE PROOF-OF-CONCEPT STUDIES FOR ACUTE MIGRAINE (TRV250) AND OPIOID USE DISORDER (TRV734). ANNOUNCES NIH COLLABORATION TO EVALUATE TRV045 FOR EPILEPSY. The summary of the amendment above is not complete and is qualified in its entirety by reference to the amendment, the copy of which is presented in Appendix 10.1 to this current report on Form 8-K and is included as a reference in this report. . May 7 (Reuters) – Trevena Inc ::TREVENA REPORTS FIRST QUARTER 2020 RESULTS. Q1 LOSS PER SHARE $0.06.
BELIEVES CASH AND CASH EQUIVALENTS AT MARCH 31 WILL BE SUFFICIENT TO FUND OPERATING EXPENSES AND CAPEX REQUIREMENTS INTO Q1 2021.